A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration

Progress in Retinal and Eye Research

Volumn 50, Issue , 2016, Pages 1-24

  Schmidt Erfurth, Ursula ^a   Waldstein, Sebastian M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Age related macular degeneration; Antiangiogenic therapy; Choroidal neovascularization; Intraretinal cystoid fluid; Intravitreal therapy; Optical coherence tomography; Pigment epithelial detachment; Predictive factors; Prognostic factors; Subretinal fluid

Indexed keywords

VASCULOTROPIN ANTIBODY; ANGIOGENESIS INHIBITOR; BIOLOGICAL MARKER;

AGE; AGE RELATED MACULAR DEGENERATION; ANGIOGRAPHY; AUTOFLUORESCENCE IMAGING; CENTRAL RETINAL THICKNESS; CENTRAL SCOTOMA; DISEASE ACTIVITY; DISEASE COURSE; GENETIC ASSOCIATION; GEOGRAPHIC ATROPHY; HUMAN; IN VIVO STUDY; INDOCYANINE GREEN ANGIOGRAPHY; METAMORPHOPSIA; MULTIMODAL IMAGING; OPTICAL COHERENCE TOMOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY; OPTICS; PHARMACOGENETICS; PIGMENT EPITHELIUM; POLARIZATION SENSITIVE OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RETINA DETACHMENT; RETINA DISEASE; RETINAL PIGMENT EPITHELIAL ATROPHY; REVIEW; SUBRETINAL NEOVASCULARIZATION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS; CHOROIDAL NEOVASCULARIZATION; FLUORESCENCE ANGIOGRAPHY; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; RISK FACTOR; SUBRETINAL FLUID;

AGE FACTORS; ANGIOGENESIS INHIBITORS; BIOMARKERS; CHOROIDAL NEOVASCULARIZATION; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; PREDICTIVE VALUE OF TESTS; RETINAL DETACHMENT; RISK FACTORS; SUBRETINAL FLUID; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 84955388945     PISSN: 13509462     EISSN: 18731635     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2015.07.007     Document Type: Review

References (249)

1. AAO Retina/Vitreous PPP Panel Age-related Macular Degeneration Preferred Practice Pattern 2015, (accessed March 2015). http://www.aao.org/ppp.
2. Abedi F., Wickremasinghe S., Islam A.F., Inglis K.M., Guymer R.H. Anti-VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 years. Retina 2014, 34:1531-1538.
3. Abedi F., Wickremasinghe S., Richardson A.J., Islam A.F., Guymer R.H., Baird P.N. Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration. Ophthalmology 2013, 120:1641-1648.
4. Abedi F., Wickremasinghe S., Richardson A.J., Makalic E., Schmidt D.F., Sandhu S.S., Baird P.N., Guymer R.H. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration. Ophthalmology 2013, 120:115-121.
5. Ahlers C., Golbaz I., Einwallner E., Dunavölgyi R., Malamos P., Stock G., Pruente C., Schmidt-Erfurth U. Identification of optical density ratios in subretinal fluid as a clinically relevant biomarker in exudative macular disease. Investig. Ophthalmol. Vis. Sci. 2009, 50:3417-3424.
6. Ahlers C., Gotzinger E., Pircher M., Golbaz I., Prager F., Schutze C., Baumann B., Hitzenberger C.K., Schmidt-Erfurth U. Imaging of the retinal pigment epithelium in age-related macular degeneration using polarization-sensitive optical coherence tomography. Investig. Ophthalmol. Vis. Sci. 2010, 51:2149-2157.
7. Ahn S.J., Ahn J., Park S., Kim H., Hwang D.J., Park J.H., Park J.Y., Chung J.Y., Park K.H., Woo S.J. Intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes. Investig. Ophthalmol. Vis. Sci. 2014, 55:567-573.
8. Akagi-Kurashige Y., Tsujikawa A., Oishi A., Ooto S., Yamashiro K., Tamura H., Nakata I., Ueda-Arakawa N., Yoshimura N. Relationship between retinal morphological findings and visual function in age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol. 2012, 250:1129-1136.
9. Altaweel M.M., Daniel E., Martin D.F., Mittra R.A., Grunwald J.E., Lai M.M., Melamud A., Morse L.S., Huang J., Ferris F.L., Fine S.L., Maguire M.G. Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). Ophthalmology 2015, 122:391-398.
10. Anderson D.H., Radeke M.J., Gallo N.B., Chapin E.A., Johnson P.T., Curletti C.R., Hancox L.S., Hu J., Ebright J.N., Malek G., Hauser M.A., Rickman C.B., Bok D., Hageman G.S., Johnson L.V. The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog. Retin. Eye Res. 2010, 29:95-112.
11. Arias L., Roman I., Masuet-Aumatell C., Rubio M.J., Caminal J.M., Catala J., Pujol O. One-year results of a flexible regimen with ranibizumab therapy in macular degeneration: relationship with the number of injections. Retina 2011, 31:1261-1267.
12. Bandukwala T., Muni R.H., Schwartz C., Eng K.T., Kertes P.J. Effectiveness of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration in a Canadian retina practice: a retrospective review. Can. J. Ophthalmol. 2010, 45:590-595.
13. Baumann B., Baumann S.O., Konegger T., Pircher M., Gotzinger E., Schlanitz F., Schutze C., Sattmann H., Litschauer M., Schmidt-Erfurth U., Hitzenberger C.K. Polarization sensitive optical coherence tomography of melanin provides intrinsic contrast based on depolarization. Biomed. Opt. Express 2012, 3:1670-1683.
14. Berg K., Pedersen T.R., Sandvik L., Bragadottir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 2015, 122:146-152.
15. Bhutto I., Lutty G. Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch's membrane/choriocapillaris complex. Mol. Aspects Med. 2012, 33:295-317.
16. Bloch S.B., la Cour M., Sander B., Hansen L.K.H., Fuchs J., Lund-Andersen H., Larsen M. Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment. Acta Ophthalmol. 2013, 91:42-47.
17. Bloch S.B., Lund-Andersen H., Sander B., Larsen M. Subfoveal fibrosis in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab. Am. J. Ophthalmol. 2013, 156. 116-124 e111.
18. Bogunovic H., Kwon Y.H., Rashid A., Lee K., Critser D.B., Garvin M.K., Sonka M., Abramoff M.D. Relationships of retinal structure and Humphrey 24-2 visual field thresholds in patients with glaucoma. Investig. Ophthalmol. Vis. Sci. 2015, 56:259-271.
19. Bolz M., Schmidt-Erfurth U., Deak G., Mylonas G., Kriechbaum K., Scholda C. Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema. Ophthalmology 2009, 116:914-920.
20. Bolz M., Simader C., Ritter M., Ahlers C., Benesch T., Pruente C., Schmidt-Erfurth U. Morphological and functional analysis of the loading regimen with intravitreal ranibizumab in neovascular age-related macular degeneration. Br. J. Ophthalmol. 2010, 94:185-189.
21. Boyer D.S., Antoszyk A.N., Awh C.C., Bhisitkul R.B., Shapiro H., Acharya N.R. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007, 114:246-252.
22. Branchini L., Regatieri C.V., Flores-Moreno I., Baumann B., Fujimoto J.G., Duker J.S. Reproducibility of choroidal thickness measurements across three spectral domain optical coherence tomography systems. Ophthalmology 2012, 119:119-123.
23. Brown D.M., Kaiser P.K., Michels M., Soubrane G., Heier J.S., Kim R.Y., Sy J.P., Schneider S. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 2006, 355:1432-1444.
24. Busbee B.G., Ho A.C., Brown D.M., Heier J.S., Suner I.J., Li Z., Rubio R.G., Lai P. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2013, 120:1046-1056.
25. Byun Y.J., Lee S.J., Koh H.J. Predictors of response after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Jpn. J. Ophthalmol. 2010, 54:571-577.
26. Campbell J.P., Bressler S.B., Bressler N.M. Impact of availability of anti-vascular endothelial growth factor therapy on visual impairment and blindness due to neovascular age-related macular degeneration. Arch. Ophthalmol. 2012, 130:794-795.
27. Castillo M.M., Mowatt G., Elders A., Lois N., Fraser C., Hernandez R., Amoaku W., Burr J.M., Lotery A., Ramsay C.R., Azuara-Blanco A. Optical coherence tomography for the monitoring of neovascular age-related macular degeneration: a systematic review. Ophthalmology 2015, 122:399-406.
28. Chakravarthy U., Harding S.P., Rogers C.A., Downes S.M., Lotery A.J., Culliford L.A., Reeves B.C. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013, 382:1258-1267.
29. Chakravarthy U., Harding S.P., Rogers C.A., Downes S.M., Lotery A.J., Wordsworth S., Reeves B.C. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012, 119:1399-1411.
30. Chakravarthy U., Wong T.Y., Fletcher A., Piault E., Evans C., Zlateva G., Buggage R., Pleil A., Mitchell P. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol. 2010, 10:31.
31. Chang L.K., Sarraf D. Tears of the retinal pigment epithelium: an old problem in a new era. Retina 2007, 27:523-534.
32. Channa R., Sophie R., Bagheri S., Shah S.M., Wang J., Adeyemo O., Sodhi A., Wenick A., Ying H.S., Campochiaro P.A. Regression of choroidal neovascularization results in macular atrophy in anti-vascular endothelial growth factor-treated eyes. Am. J. Ophthalmol. 2015, 159. 9-19 e11-12.
33. Charbel Issa P., Chong N.V., Scholl H.P. The significance of the complement system for the pathogenesis of age-related macular degeneration - current evidence and translation into clinical application. Graefes Arch. Clin. Exp. Ophthalmol. 2011, 249:163-174.
34. Chen X., Zhang L., Sohn E.H., Lee K., Niemeijer M., Chen J., Sonka M., Abramoff M.D. Quantification of external limiting membrane disruption caused by diabetic macular edema from SD-OCT. Investig. Ophthalmol. Vis. Sci. 2012, 53:8042-8048.
35. Chew E.Y., Clemons T.E., Bressler S.B., Elman M.J., Danis R.P., Domalpally A., Heier J.S., Kim J.E., Garfinkel R. Randomized trial of a home monitoring system for early detection of choroidal neovascularization Home Monitoring of the Eye (HOME) study. Ophthalmology 2014, 121:535-544.
36. Chew E.Y., Sperduto R.D., Milton R.C., Clemons T.E., Gensler G.R., Bressler S.B., Klein R., Klein B.E., Ferris F.L. Risk of advanced age-related macular degeneration after cataract surgery in the Age-Related Eye Disease Study: AREDS report 25. Ophthalmology 2009, 116:297-303.
37. Chiang A., Chang L.K., Yu F., Sarraf D. Predictors of anti-VEGF-associated retinal pigment epithelial tear using FA and OCT analysis. Retina 2008, 28:1265-1269.
38. Cho H.J., Yoo S.G., Kim H.S., Kim J.H., Kim C.G., Lee T.G., Kim J.W. Risk factors for geographic atrophy after intravitreal ranibizumab injections for retinal angiomatous proliferation. Am. J. Ophthalmol. 2015, 159:285-292.
39. Christenbury J.G., Folgar F.A., O'Connell R.V., Chiu S.J., Farsiu S., Toth C.A. Progression of intermediate age-related macular degeneration with proliferation and inner retinal migration of hyperreflective foci. Ophthalmology 2013, 120:1038-1045.
40. Christoforidis J.B., Williams M.M., Wang J., Jiang A., Pratt C., Abdel-Rasoul M., Hinkle G.H., Knopp M.V. Anatomic and pharmacokinetic properties of intravitreal bevacizumab and ranibizumab after vitrectomy and lensectomy. Retina 2013, 33:946-952.
41. Cohen S.Y., Dubois L., Nghiem-Buffet S., Ayrault S., Fajnkuchen F., Guiberteau B., Delahaye-Mazza C., Quentel G., Tadayoni R. Retinal pseudocysts in age-related geographic atrophy. Am. J. Ophthalmol. 2010, 150:211-217.
42. Cohen S.Y., Dubois L., Tadayoni R., Fajnkuchen F., Nghiem-Buffet S., Delahaye-Mazza C., Guiberteau B., Quentel G. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am. J. Ophthalmol. 2009, 148:409-413.
43. Cohen S.Y., Mimoun G., Oubraham H., Zourdani A., Malbrel C., Queré S., Schneider V. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study. Retina 2013, 33:474-481.
44. Coscas G., De Benedetto U., Coscas F., Li Calzi C.I., Vismara S., Roudot-Thoraval F., Bandello F., Souied E. Hyperreflective dots: a new spectral-domain optical coherence tomography entity for follow-up and prognosis in exudative age-related macular degeneration. Ophthalmologica 2013, 229:32-37.
45. Cuilla T.A., Ying G.-S., Maguire M.G., Martin D.F., Jaffe G.J., Grunwald J.E., Daniel E., Toth C.A. Influence of the vitreomacular interface on treatment outcomes in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2015, 122:1203-1211.
46. Curcio C.A., Medeiros N.E., Millican C.L. The Alabama Age-Related Macular Degeneration Grading System for donor eyes. Investig. Ophthalmol. Vis. Sci. 1998, 39:1085-1096.
47. Daniel E., Toth C.A., Grunwald J.E., Jaffe G.J., Martin D.F., Fine S.L., Huang J., Ying G.S., Hagstrom S.A., Winter K., Maguire M.G. Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2014, 121:656-666.
48. Dansingani K.K., Naysan J., Freund K.B. En face OCT angiography demonstrates flow in early type 3 neovascularization (retinal angiomatous proliferation). Eye (Lond.) 2015, 29:703-706.
49. de Amorim Garcia Filho C.A., Penha F.M., Gregori G., Rosenfeld P.J. Increasing volume of a retinal pigmented epithelial detachment as a predictor of submacular hemorrhage during anti-VEGF therapy. Ophthalmic Surg. Lasers Imaging Retin. 2013, 44:204-207.
50. de Sisternes L., Simon N., Tibshirani R., Leng T., Rubin D.L. Quantitative SD-OCT imaging biomarkers as indicators of age-related macular degeneration progression. Investig. Ophthalmol. Vis. Sci. 2014, 55:7093-7103.
51. Deangelis M.M., Silveira A.C., Carr E.A., Kim I.K. Genetics of age-related macular degeneration: current concepts, future directions. Semin. Ophthalmol. 2011, 26:77-93.
52. Dedania V.S., Grob S., Zhang K., Bakri S.J. Pharmacogenomics of response to anti-VEGF therapy in exudative age-related macular degeneration. Retina 2015, 35:381-391.
53. Delori F.C., Dorey C.K., Staurenghi G., Arend O., Goger D.G., Weiter J.J. In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. Investig. Ophthalmol. Vis. Sci. 1995, 36:718-729.
54. Dirani A., Ambresin A., Marchionno L., Decugis D., Mantel I. Factors influencing the treatment response of pigment epithelium detachment in age-related macular degeneration. Am. Ophthalmol. 2015 Jul 2, pii: S0002-9394(15)00380-3. doi: 10.1016/j.ajo.2015.06.025. [Epub ahead of print].
55. Dirani A., Gianniou C., Marchionno L., Decugis D., Mantel I. Incidence of outer retinal tubulation in ranibizumab-treated age-related macular degeneration. Retina 2015 Jun, 35(6):1166-1172. 10.1097/IAE.0000000000000439.
56. Duker J.S., Kaiser P.K., Binder S., de Smet M.D., Gaudric A., Reichel E., Sadda S.R., Sebag J., Spaide R.F., Stalmans P. The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology 2013, 120:2611-2619.
57. El-Emam S., Chhablani J., Barteselli G., Wang H., Lee S.N., Kozak I., Cheng L., Freeman W.R. Correlation of spectral domain optical coherence tomography characteristics with visual acuity in eyes with subfoveal scarring after treatment for wet age-related macular degeneration. Retina 2013, 33:1249-1257.
58. El-Mollayess G.M., Mahfoud Z., Schakal A.R., Salti H.I., Jaafar D., Bashshur Z.F. Fixed-interval versus OCT-guided variable dosing of intravitreal bevacizumab in the management of neovascular age-related macular degeneration: a 12-month randomized prospective study. Am. J. Ophthalmol. 2012, 153:481-489.
59. Ellabban A.A., Tsujikawa A., Ogino K., Ooto S., Yamashiro K., Oishi A., Yoshimura N. Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization. Clin. Ophthalmol. 2012, 6:837-844.
60. Esmaeelpour M., Ansari-Shahrezaei S., Glittenberg C., Nemetz S., Kraus M.F., Hornegger J., Fujimoto J.G., Drexler W., Binder S. Choroid, Haller's, and Sattler's layer thickness in intermediate age-related macular degeneration with and without fellow neovascular eyes. Investig. Ophthalmol. Vis. Sci. 2014, 55:5074-5080.
61. Faria-Correia F., Barros-Pereira R., Queiros-Mendanha L., Fonseca S., Mendonca L., Falcao M.S., Brandao E., Falcao-Reis F., Carneiro A.M. Characterization of neovascular age-related macular degeneration patients with outer retinal tubulations. Ophthalmologica 2013, 229:147-151.
62. Felberer F., Kroisamer J.S., Baumann B., Zotter S., Schmidt-Erfurth U., Hitzenberger C.K., Pircher M. Adaptive optics SLO/OCT for 3D imaging of human photoreceptors in vivo. Biomed. Opt. Express 2014, 5:439-456.
63. Fercher A.F., Hitzenberger C.K., Drexler W., Kamp G., Sattmann H. In vivo optical coherence tomography. Am. J. Ophthalmol. 1993, 116:113-114.
64. Ferris F.L., Wilkinson C.P., Bird A., Chakravarthy U., Chew E., Csaky K., Sadda S.R. Clinical classification of age-related macular degeneration. Ophthalmology 2013, 120:844-851.
65. Ferris F.L., Davis M.D., Clemons T.E., Lee L.Y., Chew E.Y., Lindblad A.S., Milton R.C., Bressler S.B., Klein R. A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Arch. Ophthalmol. 2005, 123:1570-1574.
66. Fileta J.B., Scott I.U., Flynn H.W. Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmic Surg. Lasers Imaging Retin. 2014, 45:143-149.
67. Finger R.P., Wickremasinghe S.S., Baird P.N., Guymer R.H. Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration. Surv. Ophthalmol. 2014, 59:1-18.
68. Folgar F.A., Chow J.H., Farsiu S., Wong W.T., Schuman S.G., O'Connell R.V., Winter K.P., Chew E.Y., Hwang T.S., Srivastava S.K., Harrington M.W., Clemons T.E., Toth C.A. Spatial correlation between hyperpigmentary changes on color fundus photography and hyperreflective foci on SDOCT in intermediate AMD. Investig. Ophthalmol. Vis. Sci. 2012, 53:4626-4633.
69. Forte R., Querques G., Querques L., Leveziel N., Benhamou N., Souied E.H. Multimodal evaluation of foveal sparing in patients with geographic atrophy due to age-related macular degeneration. Retina 2013, 33:482-489.
70. Freund K.B., Zweifel S.A., Engelbert M. Do we need a new classification for choroidal neovascularization in age-related macular degeneration?. Retina 2010, 30:1333-1349.
71. Fung A.E., Lalwani G.A., Rosenfeld P.J., Dubovy S.R., Michels S., Feuer W.J., Puliafito C.A., Davis J.L., Flynn H.W., Esquiabro M. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am. J. Ophthalmol. 2007, 143:566-583.
72. Funk M., Karl D., Georgopoulos M., Benesch T., Sacu S., Polak K., Zlabinger G.J., Schmidt-Erfurth U. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology 2009, 116:2393-2399.
73. Garvin M.K., Abramoff M.D., Kardon R., Russell S.R., Wu X., Sonka M. Intraretinal layer segmentation of macular optical coherence tomography images using optimal 3-D graph search. IEEE Trans. Med. Imaging 2008, 27:1495-1505.
74. Garvin M.K., Abramoff M.D., Wu X., Russell S.R., Burns T.L., Sonka M. Automated 3-D intraretinal layer segmentation of macular spectral-domain optical coherence tomography images. IEEE Trans. Med. Imaging 2009, 28:1436-1447.
75. Gass J.D. Stereoscopic Atlas of Macular Disease 1998, Mosby. fourth ed.
76. Geck U., Pustolla N., Baraki H., Atili A., Feltgen N., Hoerauf H. Posterior vitreous detachment following intravitreal drug injection. Graefes Arch. Clin. Exp. Ophthalmol. 2013, 251:1691-1695.
77. Gelman S.K., Freund K.B., Shah V.P., Sarraf D. The pearl necklace sign: a novel spectral domain optical coherence tomography finding in exudative macular disease. Retina 2014, 34:2088-2095.
78. Gerding H., Loukopoulos V., Riese J., Hefner L., Timmermann M. Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome. Graefes Arch. Clin. Exp. Ophthalmol. 2011, 249:653-662.
79. Giani A., Esmaili D.D., Luiselli C., Cigada M., Salvetti P., Miller J.W., Staurenghi G. Displayed reflectivity of choroidal neovascular membranes by optical coherence tomography correlates with presence of leakage by fluorescein angiography. Retina 2011, 31:942-948.
80. Giani A., Luiselli C., Esmaili D.D., Salvetti P., Cigada M., Miller J.W., Staurenghi G. Spectral-domain optical coherence tomography as an indicator of fluorescein angiography leakage from choroidal neovascularization. Investig. Ophthalmol. Vis. Sci. 2011, 52:5579-5586.
81. Gianniou C., Dirani A., Jang L., Mantel I. Refractory intraretinal or subretinal fluid in neovascular age-related macular degeneration treated with intravitreal ranibizumab: functional and structural outcome. Retina 2015, (in press).
82. Göbel A.P., Holz F.G., Schmitz-Valckenberg S. Development of intraretinal cystoid lesions identified by SD-OCT in eyes with intermediate age-related macular degeneration. Ophthalmologe 2014, 111(Suppl. 1):1-172.
83. Goldenberg D.T., Leverenz V.R., Giblin F.J., Drenser K.A., Trese M.T. Posterior vitreous detachment alters retinal penetration of intravitreal bevacizumab (Avastin) in rabbit eyes. Investig. Ophthalmol. Vis. Sci. 2008, 49. ARVO E-Abstract 5616.
84. Grossniklaus H.E., Green W.R. Choroidal neovascularization. Am. J. Ophthalmol. 2004, 137:496-503.
85. Grunwald J.E., Daniel E., Huang J., Ying G.S., Maguire M.G., Toth C.A., Jaffe G.J., Fine S.L., Blodi B., Klein M.L., Martin A.A., Hagstrom S.A., Martin D.F. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2014, 121:150-161.
86. Grunwald J.E., Pistilli M., Ying G.S., Maguire M.G., Daniel E., Martin D.F. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2014, 122:809-816.
87. Gupta O.P., Shienbaum G., Patel A.H., Fecarotta C., Kaiser R.S., Regillo C.D. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 2010, 117:2134-2140.
88. Hageman G.S., Luthert P.J., Chong N.V., Johnson L.V., Anderson D.H., Mullins R.F. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog. Retin. Eye Res. 2001, 20:705-732.
89. Hagstrom S.A., Ying G.S., Pauer G.J., Sturgill-Short G.M., Huang J., Callanan D.G., Kim I.K., Klein M.L., Maguire M.G., Martin D.F. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology 2013, 120:593-599.
90. Hagstrom S.A., Ying G.S., Pauer G.J., Sturgill-Short G.M., Huang J., Maguire M.G., Martin D.F. VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). JAMA Ophthalmol. 2014, 132:521-527. Comparison of Age-Related Macular Degeneration Treatments Trials Research, G.
91. Hawkes N. Avastin is as effective as Lucentis for wet AMD and could save NHS 84m pound a year, study shows. BMJ 2012, 344:e3275.
92. Hayashi H., Yamashiro K., Tsujikawa A., Ota M., Otani A., Yoshimura N. Association between foveal photoreceptor integrity and visual outcome in neovascular age-related macular degeneration. Am. J. Ophthalmol. 2009, 148:83-89.
93. Hecker L.A., Edwards A.O., Ryu E., Tosakulwong N., Baratz K.H., Brown W.L., Charbel Issa P., Scholl H.P., Pollok-Kopp B., Schmid-Kubista K.E., Bailey K.R., Oppermann M. Genetic control of the alternative pathway of complement in humans and age-related macular degeneration. Hum. Mol. Genet. 2010, 19:209-215.
94. Hee M.R., Puliafito C.A., Wong C., Duker J.S., Reichel E., Rutledge B., Schuman J.S., Swanson E.A., Fujimoto J.G. Quantitative assessment of macular edema with optical coherence tomography. Arch. Ophthalmol. 1995, 113:1019-1029.
95. Heimes B., Lommatzsch A., Zeimer M., Gutfleisch M., Spital G., Pauleikhoff D. Anti-VEGF therapy of exudative AMD: prognostic factors for therapy success. Ophthalmologe 2011, 108:124-131.
96. Hemeida T.S., Keane P.A., Dustin L., Sadda S.R., Fawzi A.A. Long-term visual and anatomical outcomes following anti-VEGF monotherapy for retinal angiomatous proliferation. Br. J. Ophthalmol. 2010, 94:701-705.
97. Hirata M., Tsujikawa A., Matsumoto A., Hangai M., Ooto S., Yamashiro K., Akiba M., Yoshimura N. Macular choroidal thickness and volume in normal subjects measured by swept-source optical coherence tomography. Investig. Ophthalmol. Vis. Sci. 2011, 52:4971-4978.
98. Hjelmqvist L., Lindberg C., Kanulf P., Dahlgren H., Johansson I., Siewert A. One-year outcomes using ranibizumab for neovascular age-related macular degeneration: results of a prospective and retrospective observational multicentre study. J. Ophthalmol. 2011, 2011:405724.
99. Ho J., Sull A.C., Vuong L.N., Chen Y., Liu J., Fujimoto J.G., Schuman J.S., Duker J.S. Assessment of artifacts and reproducibility across spectral- and time-domain optical coherence tomography devices. Ophthalmology 2009, 116:1960-1970.
100. Hogg R.E., Silva R., Staurenghi G., Murphy G., Santos A.R., Rosina C., Chakravarthy U. Clinical characteristics of reticular pseudodrusen in the fellow eye of patients with unilateral neovascular age-related macular degeneration. Ophthalmology 2014, 121:1748-1755.
101. Holz F.G., Amoaku W., Donate J., Guymer R.H., Kellner U., Schlingemann R.O., Weichselberger A., Staurenghi G. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011, 118:663-671.
102. Holz F.G., Bindewald-Wittich A., Fleckenstein M., Dreyhaupt J., Scholl H.P., Schmitz-Valckenberg S. Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration. Am. J. Ophthalmol. 2007, 143:463-472.
103. Holz F.G., Tadayoni R., Beatty S., Berger A., Cereda M.G., Cortez R., Hoyng C.B., Hykin P., Staurenghi G., Heldner S., Bogumil T., Heah T., Sivaprasad S. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br. J. Ophthalmol. 2015, 99:220-226.
104. Hong Y.J., Miura M., Ju M.J., Makita S., Iwasaki T., Yasuno Y. Simultaneous investigation of vascular and retinal pigment epithelial pathologies of exudative macular diseases by multifunctional optical coherence tomography. Investig. Ophthalmol. Vis. Sci. 2014, 55:5016-5031.
105. Horster R., Ristau T., Sadda S.R., Liakopoulos S. Individual recurrence intervals after anti-VEGF therapy for age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol. 2011, 249:645-652.
106. Huang D., Swanson E.A., Lin C.P., Schuman J.S., Stinson W.G., Chang W., Hee M.R., Flotte T., Gregory K., Puliafito C.A., et al. Optical coherence tomography. Science 1991, 254:1178-1181.
107. Itakura H., Kishi S. Evolution of vitreomacular detachment in healthy subjects. JAMA Ophthalmol. 2013, 131:1348-1352.
108. Jaffe G.J., Martin D.F., Toth C.A., Daniel E., Maguire M.G., Ying G.S., Grunwald J.E., Huang J. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2013, 120:1860-1870.
109. Jia Y., Bailey S.T., Wilson D.J., Tan O., Klein M.L., Flaxel C.J., Potsaid B., Liu J.J., Lu C.D., Kraus M.F., Fujimoto J.G., Huang D. Quantitative optical coherence tomography angiography of choroidal neovascularization in age-related macular degeneration. Ophthalmology 2014, 121:1435-1444.
110. Jung J.J., Chen C.Y., Mrejen S., Gallego-Pinazo R., Xu L., Marsiglia M., Boddu S., Freund K.B. The incidence of neovascular subtypes in newly diagnosed neovascular age-related macular degeneration. Am. J. Ophthalmol. 2014, 158:769-779.
111. Kaiser P.K., Boyer D.S., Cruess A.F., Slakter J.S., Pilz S., Weisberger A. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology 2012, 119:1001-1010.
112. Kaiser P.K., Brown D.M., Zhang K., Hudson H.L., Holz F.G., Shapiro H., Schneider S., Acharya N.R. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am. J. Ophthalmol. 2007, 144:850-857.
113. Kanagasingam Y., Bhuiyan A., Abramoff M.D., Smith R.T., Goldschmidt L., Wong T.Y. Progress on retinal image analysis for age related macular degeneration. Prog. Retin. Eye Res. 2014, 38:20-42.
114. Kashani A.H., Keane P.A., Dustin L., Walsh A.C., Sadda S.R. Quantitative subanalysis of cystoid spaces and outer nuclear layer using optical coherence tomography in age-related macular degeneration. Investig. Ophthalmol. Vis. Sci. 2009, 50:3366-3373.
115. Katz G., Giavedoni L., Muni R., Evans T., Pezda M., Wong D., Moffat A., Altomare F., Boyd S., Berger A. Effectiveness at 1 year of monthly versus variable-dosing intravitreal ranibizumab in the treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2012, 32:293-298.
116. Keane P.A., Liakopoulos S., Chang K.T., Wang M., Dustin L., Walsh A.C., Sadda S.R. Relationship between optical coherence tomography retinal parameters and visual acuity in neovascular age-related macular degeneration. Ophthalmology 2008, 115:2206-2214.
117. Keane P.A., Patel P.J., Liakopoulos S., Heussen F.M., Sadda S.R., Tufail A. Evaluation of age-related macular degeneration with optical coherence tomography. Surv. Ophthalmol. 2012, 57:389-414.
118. Keane P.A., Patel P.J., Ouyang Y., Chen F.K., Ikeji F., Walsh A.C., Tufail A., Sadda S.R. Effects of retinal morphology on contrast sensitivity and reading ability in neovascular age-related macular degeneration. Investig. Ophthalmol. Vis. Sci. 2010, 51:5431-5437.
119. Kim Y.M., Kim J.H., Koh H.J. Improvement of photoreceptor integrity and associated visual outcome in neovascular age-related macular degeneration. Am. J. Ophthalmol. 2012, 154:164-173.
120. Koizumi H., Yamagishi T., Yamazaki T., Kawasaki R., Kinoshita S. Subfoveal choroidal thickness in typical age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch. Clin. Exp. Ophthalmol. 2011, 249:1123-1128.
121. Krebs I., Brannath W., Glittenberg C., Zeiler F., Sebag J., Binder S. Posterior vitreomacular adhesion: a potential risk factor for exudative age-related macular degeneration?. Am. J. Ophthalmol. 2007, 144:741-746.
122. Krebs I., Falkner-Radler C., Hagen S., Haas P., Brannath W., Lie S., Ansari-Shahrezaei S., Binder S. Quality of the threshold algorithm in age-related macular degeneration: stratus versus cirrus OCT. Investig. Ophthalmol. Vis. Sci. 2009, 50:995-1000.
123. Krebs I., Glittenberg C., Zeiler F., Binder S. Spectral domain optical coherence tomography for higher precision in the evaluation of vitreoretinal adhesions in exudative age-related macular degeneration. Br. J. Ophthalmol. 2011, 95:1415-1418.
124. Kumar A., Sahni J.N., Stangos A.N., Campa C., Harding S.P. Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinician-determined retreatment strategy. Br. J. Ophthalmol. 2011, 95:530-533.
125. Kumar N., Mrejen S., Fung A.T., Marsiglia M., Loh B.K., Spaide R.F. Retinal pigment epithelial cell loss assessed by fundus autofluorescence imaging in neovascular age-related macular degeneration. Ophthalmology 2013, 120:334-341.
126. Lalwani G.A., Rosenfeld P.J., Fung A.E., Dubovy S.R., Michels S., Feuer W., Davis J.L., Flynn H.W., Esquiabro M. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am. J. Ophthalmol. 2009, 148:43-58.
127. Larsen M., Schmidt-Erfurth U., Lanzetta P., Wolf S., Simader C., Tokaji E., Pilz S., Weisberger A. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results. Ophthalmology 2012, 119:992-1000.
128. Lee J.Y., Folgar F.A., Maguire M.G., Ying G.S., Toth C.A., Martin D.F., Jaffe G.J. Outer retinal tubulation in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology 2014, 121:2423-2431.
129. Lee S.J., Koh H.J. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration. Ophthalmology 2011, 118:101-110.
130. Lee S.J., Lee C.S., Koh H.J. Posterior vitreomacular adhesion and risk of exudative age-related macular degeneration: paired eye study. Am. J. Ophthalmol. 2009, 147:621-626.
131. Leitgeb R.A., Werkmeister R.M., Blatter C., Schmetterer L. Doppler optical coherence tomography. Prog. Retin. Eye Res. 2014, 41:26-43.
132. Leydolt C., Michels S., Prager F., Garhoefer G., Georgopoulos M., Polak K., Schmidt-Erfurth U. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results. Acta Ophthalmol. 2010, 88:594-600.
133. Liakopoulos S., Ongchin S., Bansal A., Msutta S., Walsh A.C., Updike P.G., Sadda S.R. Quantitative optical coherence tomography findings in various subtypes of neovascular age-related macular degeneration. Investig. Ophthalmol. Vis. Sci. 2008, 49:5048-5054.
134. Lim J.H., Wickremasinghe S.S., Xie J., Chauhan D.S., Baird P.N., Robman L.D., Hageman G., Guymer R.H. Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration. Am. J. Ophthalmol. 2012, 153:678-686.
135. Lim L.S., Mitchell P., Seddon J.M., Holz F.G., Wong T.Y. Age-related macular degeneration. Lancet 2012, 379:1728-1738.
136. Litts K.M., Messinger J.D., Dellatorre K., Yannuzzi L.A., Freund K.B., Curcio C.A. Clinicopathological correlation of outer retinal tubulation in age-related macular degeneration. JAMA Ophthalmol. 2015, 133:609-612.
137. Litts K.M., Messinger J.D., Freund K.B., Zhang Y., Curcio C.A. Inner segment remodeling and mitochondrial translocation in cone photoreceptors in age-related macular degeneration with outer retinal tubulation. Investig. Ophthalmol. Vis. Sci. 2015, 56:2243-2253.
138. Liu M., Wang P.-W., Haskova Z. Baseline predictors of early visual acuity improvement in RVO patients treated with ranibizumab in the SHORE study. Investig. Ophthalmol. Vis. Sci. 2015, ARVO E-Abstract 5802.
139. Lotery A.J., Gibson J., Cree A.J., Downes S.M., Harding S.P., Rogers C.A., Reeves B.C., Ennis S., Chakravarthy U. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN study. Ophthalmology 2013, 120:2637-2643.
140. Martin D.F., Maguire M.G., Fine S.L., Ying G.S., Jaffe G.J., Grunwald J.E., Toth C., Redford M., Ferris F.L. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012, 119:1388-1398.
141. Martin D.F., Maguire M.G., Ying G.S., Grunwald J.E., Fine S.L., Jaffe G.J. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2011, 364:1897-1908.
142. Mathew R., Richardson M., Sivaprasad S. Predictive value of spectral-domain optical coherence tomography features in assessment of visual prognosis in eyes with neovascular age-related macular degeneration treated with ranibizumab. Am. J. Ophthalmol. 2013, 155:720-726.
143. Mayr-Sponer U., Waldstein S.M., Kundi M., Ritter M., Golbaz I., Heiling U., Papp A., Simader C., Schmidt-Erfurth U. Influence of the vitreomacular interface on outcomes of ranibizumab therapy in neovascular age-related macular degeneration. Ophthalmology 2013, 120:2620-2629.
144. McBain V.A., Kumari R., Townend J., Lois N. Geographic atrophy in retinal angiomatous proliferation. Retina 2011, 31:1043-1052.
145. McDonnell E.C., Heussen F.M., Ruiz-Garcia H., Ouyang Y., Narala R., Walsh A.C., Sadda S.R. Effect of anti-VEGF treatment on choroidal thickness over time in patients with neovascular age-related macular degeneration. Eur. J. Ophthalmol. 2014, 24:897-903.
146. McLeod D.S., Grebe R., Bhutto I., Merges C., Baba T., Lutty G.A. Relationship between RPE and choriocapillaris in age-related macular degeneration. Investig. Ophthalmol. Vis. Sci. 2009, 50:4982-4991.
147. Mekjavic P.J., Kraut A., Urbancic M., Lenassi E., Hawlina M. Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections. Acta Ophthalmol. 2011, 89:647-653.
148. Meyer C.H., Michels S., Rodrigues E.B., Hager A., Mennel S., Schmidt J.C., Helb H.M., Farah M.E. Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections. Acta Ophthalmol. 2011, 89:70-75.
149. Mirza R.G., Johnson M.W., Jampol L.M. Optical coherence tomography use in evaluation of the vitreoretinal interface: a review. Surv. Ophthalmol. 2007, 52:397-421.
150. Miura M., Makita S., Iwasaki T., Yasuno Y. Three-dimensional visualization of ocular vascular pathology by optical coherence angiography in vivo. Investig. Ophthalmol. Vis. Sci. 2011, 52:2689-2695.
151. Modi Y.S., Tanchon C., Ehlers J.P. Comparative safety and tolerability of anti-VEGF therapy in age-related macular degeneration. Drug Saf. 2015, 38:279-293.
152. Montuoro A., Wu J., Waldstein S., Gerendas B., Langs G., Simader C., Schmidt-Erfurth U. Motion artefact correction in retinal optical coherence tomography using local symmetry. Medical Image Computing and Computer-Assisted Intervention - MICCAI 2014 2014, 130-137. Springer International Publishing. P. Golland, N. Hata, C. Barillot, J. Hornegger, R. Howe (Eds.).
153. Moult E., Choi W., Waheed N.K., Adhi M., Lee B., Lu C.D., Jayaraman V., Potsaid B., Rosenfeld P.J., Duker J.S., Fujimoto J.G. Ultrahigh-speed swept-source OCT angiography in exudative AMD. Ophthalmic Surg. Lasers Imaging Retin. 2014, 45:496-505.
154. Moutray T., Alarbi M., Mahon G., Stevenson M., Chakravarthy U. Relationships between clinical measures of visual function, fluorescein angiographic and optical coherence tomography features in patients with subfoveal choroidal neovascularisation. Br. J. Ophthalmol. 2008, 92:361-364.
155. MPS Study Group Age-related macular degeneration. The Macular Photocoagulation Study. Am. J. Ophthalmol. 1984, 98:376-377.
156. Mrejen S., Sato T., Curcio C.A., Spaide R.F. Assessing the cone photoreceptor mosaic in eyes with pseudodrusen and soft Drusen in vivo using adaptive optics imaging. Ophthalmology 2014, 121:545-551.
157. Mrejen S., Spaide R.F. Optical coherence tomography: imaging of the choroid and beyond. Surv. Ophthalmol. 2013, 58:387-429.
158. Mullins R.F., Khanna A., Schoo D.P., Tucker B.A., Sohn E.H., Drack A.V., Stone E.M. Is age-related macular degeneration a microvascular disease?. Adv. Exp. Med. Biol. 2014, 801:283-289.
159. Nagiel A., Freund K.B., Spaide R.F., Munch I.C., Larsen M., Sarraf D. Mechanism of retinal pigment epithelium tear formation following intravitreal anti-vascular endothelial growth factor therapy revealed by spectral-domain optical coherence tomography. Am. J. Ophthalmol. 2013, 156:981-988.
160. Nagiel A., Sarraf D., Sadda S.R., Spaide R.F., Jung J.J., Bhavsar K.V., Ameri H., Querques G., Freund K.B. Type 3 neovascularization: evolution, association with pigment epithelial detachment, and treatment response as revealed by spectral domain optical coherence tomography. Retina 2015, 35:638-647.
161. Neudorfer M., Weinberg A., Loewenstein A., Barak A. Differential optical density of subretinal spaces. Investig. Ophthalmol. Vis. Sci. 2012, 53:3104-3110.
162. Oishi A., Hata M., Shimozono M., Mandai M., Nishida A., Kurimoto Y. The significance of external limiting membrane status for visual acuity in age-related macular degeneration. Am. J. Ophthalmol. 2010, 150:27-32.
163. Oishi A., Shimozono M., Mandai M., Hata M., Nishida A., Kurimoto Y. Recovery of photoreceptor outer segments after anti-VEGF therapy for age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol. 2013, 251:435-440.
164. Ouyang Y., Heussen F.M., Hariri A., Keane P.A., Sadda S.R. Optical coherence tomography-based observation of the natural history of drusenoid lesion in eyes with dry age-related macular degeneration. Ophthalmology 2013, 120:2656-2665.
165. Ouyang Y., Heussen F.M., Mokwa N., Walsh A.C., Durbin M.K., Keane P.A., Sanchez P.J., Ruiz-Garcia H., Sadda S.R. Spatial distribution of posterior pole choroidal thickness by spectral domain optical coherence tomography. Investig. Ophthalmol. Vis. Sci. 2011, 52:7019-7026.
166. Park U.C., Shin J.Y., Kim S.J., Shin E.S., Lee J.E., McCarthy L.C., Newcombe P.J., Xu C.F., Chung H., Yu H.G. Genetic factors associated with response to intravitreal ranibizumab in Korean patients with neovascular age-related macular degeneration. Retina 2014, 34:288-297.
167. Patel P.J., Tufail A. Optimizing individualized therapy with bevacizumab for neovascular age-related macular degeneration. Retina 2012, 10.1097/IAE.0b013e31823f0ba3.
168. Pelosini L., Hull C.C., Boyce J.F., McHugh D., Stanford M.R., Marshall J. Optical coherence tomography may be used to predict visual acuity in patients with macular edema. Investig. Ophthalmol. Vis. Sci. 2011, 52:2741-2748.
169. Penha F.M., Gregori G., Garcia Filho C.A., Yehoshua Z., Feuer W.J., Rosenfeld P.J. Quantitative changes in retinal pigment epithelial detachments as a predictor for retreatment with anti-VEGF therapy. Retina 2013, 33:459-466.
170. Penha F.M., Rosenfeld P.J., Gregori G., Falcao M., Yehoshua Z., Wang F., Feuer W.J. Quantitative imaging of retinal pigment epithelial detachments using spectral-domain optical coherence tomography. Am. J. Ophthalmol. 2012, 153:515-523.
171. Pircher M., Hitzenberger C.K., Schmidt-Erfurth U. Polarization sensitive optical coherence tomography in the human eye. Prog. Retin. Eye Res. 2011, 30:431-451.
172. Querques G., Coscas F., Forte R., Massamba N., Sterkers M., Souied E.H. Cystoid macular degeneration in exudative age-related macular degeneration. Am. J. Ophthalmol. 2011, 152:100-107.
173. Querques G., Rousseau A., Forte R., Scemama C., Caillaux V., Querques L., Souied E.H. Longitudinal anatomical response of retinal-choroidal anastomosis to anti-vascular endothelial growth factor therapy. Retina 2012, 32:458-467.
174. Rahimy E., Freund K.B., Larsen M., Spaide R.F., Costa R.A., Hoang Q., Christakopoulos C., Munch I.C., Sarraf D. Multilayered pigment epithelial detachment in neovascular age-related macular degeneration. Retina 2014, 34:1289-1295.
175. Rayess N., Houston S.K., Gupta O.P., Ho A.C., Regillo C.D. Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen. Am. J. Ophthalmol. 2015, 159:3-8.
176. Regillo C.D., Brown D.M., Abraham P., Yue H., Ianchulev T., Schneider S., Shams N. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am. J. Ophthalmol. 2008, 145:239-248. e235.
177. Reynolds R., Hartnett M.E., Atkinson J.P., Giclas P.C., Rosner B., Seddon J.M. Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. Investig. Ophthalmol. Vis. Sci. 2009, 50:5818-5827.
178. Ristau T., Keane P.A., Walsh A.C., Engin A., Mokwa N., Kirchhof B., Sadda S.R., Liakopoulos S. Relationship between visual acuity and spectral domain optical coherence tomography retinal parameters in neovascular age-related macular degeneration. Ophthalmologica 2014, 231:37-44.
179. Ritter M., Simader C., Bolz M., Deák G.G., Mayr-Sponer U., Sayegh R., Kundi M., Schmidt-Erfurth U.M. Intraretinal cysts are the most relevant prognostic biomarker in neovascular age-related macular degeneration independent of the therapeutic strategy. Br. J. Ophthalmol. 2014, 98:1629-1635.
180. Roberts P., Mittermueller T.J., Montuoro A., Sulzbacher F., Munk M.R., Sacu S., Schmidt-Erfurth U. A quantitative approach to identify morphological features relevant for visual function in ranibizumab therapy of neovascular AMD. Investig. Ophthalmol. Vis. Sci. 2014, 55:6623-6630.
181. Rosenfeld P.J., Brown D.M., Heier J.S., Boyer D.S., Kaiser P.K., Chung C.Y., Kim R.Y. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2006, 355:1419-1431.
182. Rossi E.A., Rangel-Fonseca P., Parkins K., Fischer W., Latchney L.R., Folwell M.A., Williams D.R., Dubra A., Chung M.M. In vivo imaging of retinal pigment epithelium cells in age related macular degeneration. Biomed. Opt. Express 2013, 4:2527-2539.
183. Sadda, S.R., Tuomi, L., Ding, B., Hopkins, J.J., 2014. Development of atrophy in neovascular AMD treated with anti-VEGF therapy: results of the HARBOR study. American Academy of Ophthalmology Annual Meeting, Presented at Retina 2014 Subspecialty Day.
184. Sadda S.R., Wu Z., Walsh A.C., Richine L., Dougall J., Cortez R., LaBree L.D. Errors in retinal thickness measurements obtained by optical coherence tomography. Ophthalmology 2006, 113:285-293.
185. Sarraf D., Chan C., Rahimy E., Abraham P. Prospective evaluation of the incidence and risk factors for the development of RPE tears after high- and low-dose ranibizumab therapy. Retina 2013, 33:1551-1557.
186. Sarraf D., Joseph A., Rahimy E. Retinal pigment epithelial tears in the era of intravitreal pharmacotherapy: risk factors, pathogenesis, prognosis and treatment (an American Ophthalmological Society thesis). Trans. Am. Ophthalmol. Soc. 2014, 112:142-159.
187. Sato T., Suzuki M., Ooto S., Spaide R.F. Multimodal imaging findings and multimodal vision testing in neovascular age-related macular degeneration. Retina 2015, 35:1292-1302.
188. Sayegh R.G., Simader C., Scheschy U., Montuoro A., Kiss C., Sacu S., Kreil D.P., Prunte C., Schmidt-Erfurth U. A systematic comparison of spectral-domain optical coherence tomography and fundus autofluorescence in patients with geographic atrophy. Ophthalmology 2011, 118:1844-1851.
189. Schaal K.B., Freund K.B., Litts K.M., Zhang Y., Messinger J.D., Curcio C.A. Outer retinal tubulation in advanced age-related macular degeneration: optical coherence tomographic findings correspond to histology. Retina 2015, 35:1339-1350.
190. Schachat A.P., Thompson J.T. Optical coherence tomography, fluorescein angiography, and the management of neovascular age-related macular degeneration. Ophthalmology 2015, 122:222-223.
191. Schlanitz F.G., Baumann B., Spalek T., Schutze C., Ahlers C., Pircher M., Gotzinger E., Hitzenberger C.K., Schmidt-Erfurth U. Performance of automated drusen detection by polarization-sensitive optical coherence tomography. Investig. Ophthalmol. Vis. Sci. 2011, 52:4571-4579.
192. Schlegl T., Waldstein S.M., Schmidt-Erfurth U., Langs G. Predicting semantic descriptions from medical images with convolutional neural networks. Inf. Process Med. Imaging 2015, 437-448. 10.1007/978-3-319-19992-4_34.
193. Schmidt-Erfurth U., Chong V., Loewenstein A., Larsen M., Souied E., Schlingemann R., Eldem B., Monés J., Richard G., Bandello F. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br. J. Ophthalmol. 2014, 98:1144-1167.
194. Schmidt-Erfurth U., Eldem B., Guymer R., Korobelnik J.F., Schlingemann R.O., Axer-Siegel R., Wiedemann P., Simader C., Gekkieva M., Weichselberger A. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 2011, 118:831-839.
195. Schmidt-Erfurth U., Kaiser P.K., Korobelnik J.F., Brown D.M., Chong V., Nguyen Q.D., Ho A.C., Ogura Y., Simader C., Jaffe G.J., Slakter J.S., Yancopoulos G.D., Stahl N., Vitti R., Berliner A.J., Soo Y., Anderesi M., Sowade O., Zeitz O., Norenberg C., Sandbrink R., Heier J.S. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 2014, 121:193-201.
196. Schmidt-Erfurth U., Waldstein S.M., Deak G.G., Kundi M., Simader C. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. Ophthalmology 2015, 122:822-832.
197. Schmitz-Valckenberg S., Holz F.G., Bird A.C., Spaide R.F. Fundus autofluorescence imaging: review and perspectives. Retina 2008, 28:385-409.
198. Scholl H.P., Charbel Issa P., Walier M., Janzer S., Pollok-Kopp B., Borncke F., Fritsche L.G., Chong N.V., Fimmers R., Wienker T., Holz F.G., Weber B.H., Oppermann M. Systemic complement activation in age-related macular degeneration. PLoS One 2008, 3:e2593.
199. Schulze S., Hoerle S., Mennel S., Kroll P. Vitreomacular traction and exudative age-related macular degeneration. Acta Ophthalmol. 2008, 86:470-481.
200. Schutze C., Wedl M., Baumann B., Pircher M., Hitzenberger C.K., Schmidt-Erfurth U. Progression of retinal pigment epithelial atrophy in antiangiogenic therapy of neovascular age-related macular degeneration. Am. J. Ophthalmol. 2015, 159:1100-1114.e1.
201. Sebag J. Anomalous posterior vitreous detachment: a unifying concept in vitreo-retinal disease. Graefes Arch. Clin. Exp. Ophthalmol. 2004, 242:690-698.
202. Shah V.P., Shah S.A., Mrejen S., Freund K.B. Subretinal hyperreflective exudation associated with neovascular age-related macular degeneration. Retina 2014, 34:1281-1288.
203. Shin H.J., Chung H., Kim H.C. Association between foveal microstructure and visual outcome in age-related macular degeneration. Retina 2011, 31:1627-1636.
204. Shin J.Y., Kwon K.Y., Byeon S.H. Association between choroidal thickness and the response to intravitreal ranibizumab injection in age-related macular degeneration. Acta Ophthalmol. 2015 Jan 11, [Epub ahead of print]. 10.1111/aos.12653.
205. Simader C., Ritter M., Bolz M., Deak G., Sponer U., Golbaz I., Kundi M., Schmidt-Erfurth U. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Ophthalmology 2014, 121:1237-1245.
206. Singh R.S., Kim J.E. Ocular hypertension following intravitreal anti-vascular endothelial growth factor agents. Drug Aging 2012, 29:949-956.
207. Smailhodzic D., Muether P.S., Chen J., Kwestro A., Zhang A.Y., Omar A., Van de Ven J.P., Keunen J.E., Kirchhof B., Hoyng C.B., Klevering B.J., Koenekoop R.K., Fauser S., den Hollander A.I. Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration. Ophthalmology 2012, 119:2304-2311.
208. Sophie R., Lu N., Campochiaro P.A. Predictors of functional and anatomic outcomes in patients with diabetic macular edema treated with ranibizumab. Ophthalmology 2015, 122:1395-1401.
209. Spaide R.F. Visualization of the posterior vitreous with dynamic focusing and windowed averaging swept source optical coherence tomography. Am. J. Ophthalmol. 2014, 158:1267-1274.
210. Spaide R.F., Curcio C.A. Anatomical correlates to the bands seen in the outer retina by optical coherence tomography: literature review and model. Retina 2011, 31:1609-1619.
211. Spaide R.F., Laud K., Fine H.F., Klancnik J.M., Meyerle C.B., Yannuzzi L.A., Sorenson J., Slakter J., Fisher Y.L., Cooney M.J. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006, 26:383-390.
212. Staurenghi G., Sadda S., Chakravarthy U., Spaide R.F. Proposed lexicon for anatomic landmarks in normal posterior segment spectral-domain optical coherence tomography: the IN*OCT consensus. Ophthalmology 2014, 121:1572-1578.
213. Steinberg J.S., Fitzke F.W., Fimmers R., Fleckenstein M., Holz F.G., Schmitz-Valckenberg S. Scotopic and photopic microperimetry in patients with reticular drusen and age-related macular degeneration. JAMA Ophthalmol. 2015, 133:690-697.
214. Stone E.M. Genetic testing for age-related macular degeneration: not indicated now. JAMA Ophthalmol. 2015, 133:598-600.
215. Sulzbacher F., Kiss C., Kaider A., Eisenkoelbl S., Munk M., Roberts P., Sacu S., Schmidt-Erfurth U. Correlation of SD-OCT features and retinal sensitivity in neovascular age-related macular degeneration. Investig. Ophthalmol. Vis. Sci. 2012, 53:6448-6455.
216. Sulzbacher F., Kiss C., Kaider A., Roberts P., Munk M., Kroh M.E., Sayegh R., Schmidt-Erfurth U. Correlation of OCT characteristics and retinal sensitivity in neovascular age-related macular degeneration in the course of monthly ranibizumab treatment. Investig. Ophthalmol. Vis. Sci. 2013, 54:1310-1315.
217. Takahashi H., Nomura Y., Tan X., Fujino Y., Kawashima H., Yanagi Y. Effects of posterior vitreous detachment on aqueous humour levels of VEGF and inflammatory cytokines. Br. J. Ophthalmol. 2015, 99:1065-1069.
218. TAP Study Group Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch. Ophthalmol. 2001, 119:198-207.
219. Tolentino M.J., Dennrick A., John E., Tolentino M.S. Drugs in Phase II clinical trials for the treatment of age-related macular degeneration. Exp. Opin. Investig. Drugs 2015, 24:183-199.
220. Tufail A., Xing W., Johnston R., Akerele T., McKibbin M., Downey L., Natha S., Chakravarthy U., Bailey C., Khan R., Antcliff R., Armstrong S., Varma A., Kumar V., Tsaloumas M., Mandal K., Bunce C. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. Ophthalmology 2014, 121:1092-1101.
221. Viola F., Levi G., Danzi P., Veronese C., Luiselli C., Cigada M., Staurenghi G. The fellow eye in retinal angiomatous proliferation (RAP). Investig. Ophthalmol. Vis. Sci. 2005, 46. E-Abstract 244.
222. VIP Study Group Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am. J. Ophthalmol. 2001, 131:541-560.
223. Vogl W.-D., Waldstein S.M., Gerendas B.S., Wu J., Montuoro A., Glodan A.M., Podkowinski D., Simader C., Schmidt-Erfurth U., Langs G. Spatio-temporal signatures to predict retinal disease recurrence. Inf. Process Med. Imaging 2015, 152-163. 10.1007/978-3-319-19992-4_12.
224. Waldstein S.M., Gerendas B.S., Montuoro A., Simader C., Schmidt-Erfurth U. Quantitative comparison of macular segmentation performance using identical retinal regions across multiple spectral-domain optical coherence tomography instruments. Br. J. Ophthalmol. 2015, 99:794-800.
225. Waldstein S.M., Philip A.M., Leitner R., Simader C., Gerendas B., Schmidt-Erfurth U. Correlation of three-dimensionally quantified intra- and subretinal fluid with visual acuity in neovascular age-related macular degeneration. JAMA Ophthalmol 2015, (submitted for publication-a).
226. Waldstein S.M., Ritter M., Simader C., Mayr-Sponer U., Kundi M., Schmidt-Erfurth U. Impact of vitreomacular adhesion on ranibizumab mono- and combination therapy for neovascular age-related macular degeneration. Am. J. Ophthalmol. 2014, 158:328-336.
227. Waldstein S.M., Simader C., Staurenghi G., Chong N.V., Mitchell P., Schmidt-Erfurth U. Morphological and functional efficacy of aflibercept and ranibizumab in neovascular age-related macular degeneration. J. Ophthalmol. 2015, (submitted for publication-b).
228. Waldstein S.M., Sponer U., Simader C., Sacu S., Schmidt-Erfurth U. Influence of vitreomacular adhesion on the development of exudative age-related macular degeneration: 4-year results of a longitudinal study. Retina 2012, 32:424-433.
229. Waldstein, S.M., Wright, J., Warburton, J., Margaron, P., Simader, C., Schmidt-Erfurth, U., 2015d. Predictive importance of retinal morphology on visual acuity outcomes of different ranibizumab treatment regimens for neovascular AMD (submitted for publication-c).
230. Wei W.B., Xu L., Jonas J.B., Shao L., Du K.F., Wang S., Chen C.X., Xu J., Wang Y.X., Zhou J.Q., You Q.S. Subfoveal choroidal thickness: the Beijing eye study. Ophthalmology 2013, 120:175-180.
231. Whitmore S.S., Sohn E.H., Chirco K.R., Drack A.V., Stone E.M., Tucker B.A., Mullins R.F. Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy. Prog. Retin. Eye Res. 2015, 45c:1-29.
232. Wickremasinghe S.S., Xie J., Lim J., Chauhan D.S., Robman L., Richardson A.J., Hageman G., Baird P.N., Guymer R. Variants in the APOE gene are associated with improved outcome after anti-VEGF treatment for neovascular AMD. Investig. Ophthalmol. Vis. Sci. 2011, 52:4072-4079.
233. Willoughby A.S., Ying G.-S., Toth C.A., Maguire M.G., Burns R.E., Grunwald J.E., Daniel E., Jaffe G.J. Subretinal hyperreflective material in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2015, 122:1846-1853.
234. Wu J., Gerendas B.S., Waldstein S.M., Langs G., Simader C., Schmidt-Erfurth U. Stable registration of pathological 3D SD-OCT scans using retinal vessels. Ophthalmic Medical Image Analysis First International Workshop, Held in Conjunction with MICCAI 2014 2014, 1-8. Iowa Research Online, Boston, Massachusetts. X. Chen, M.K. Garvin, J.J. Liu (Eds.).
235. Wu Z., Luu C.D., Ayton L.N., Goh J.K., Lucci L.M., Hubbard W.C., Hageman J.L., Hageman G.S., Guymer R.H. Optical coherence tomography-defined changes preceding the development of drusen-associated atrophy in age-related macular degeneration. Ophthalmology 2014, 121:2415-2422.
236. Xu L., Mrejen S., Jung J.J., Gallego-Pinazo R., Thompson D., Marsiglia M., Freund K.B. Geographic atrophy in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Retina 2015, 35:176-186.
237. Xu X., Lee K., Zhang L., Sonka M., Abramoff M. Stratified sampling voxel classification for segmentation of intraretinal and subretinal fluid in longitudinal clinical OCT data. IEEE Trans. Med. Imaging 2015, 34:1616-1623.
238. Yamazaki T., Koizumi H., Yamagishi T., Kinoshita S. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results. Ophthalmology 2012, 119:1621-1627.
239. Yehoshua Z., Wang F., Rosenfeld P.J., Penha F.M., Feuer W.J., Gregori G. Natural history of drusen morphology in age-related macular degeneration using spectral domain optical coherence tomography. Ophthalmology 2011, 118:2434-2441.
240. Ying G.S., Huang J., Maguire M.G., Jaffe G.J., Grunwald J.E., Toth C., Daniel E., Klein M., Pieramici D., Wells J., Martin D.F. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2013, 120:122-129.
241. Ying G.S., Kim B.J., Maguire M.G., Huang J., Daniel E., Jaffe G.J., Grunwald J.E., Blinder K.J., Flaxel C.J., Rahhal F., Regillo C., Martin D.F. Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials. JAMA Ophthalmol. 2014, 132:915-921.
242. Yiu G., Chiu S.J., Petrou P.A., Stinnett S., Sarin N., Farsiu S., Chew E.Y., Wong W.T., Toth C.A. Relationship of central choroidal thickness with age-related macular degeneration status. Am. J. Ophthalmol. 2015, 159:617-626. e612.
243. Young M., Chui L., Fallah N., Or C., Merkur A.B., Kirker A.W., Albiani D.A., Forooghian F. Exacerbation of choroidal and retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration. Retina 2014, 34:1308-1315.
244. Zarbin M.A. Current concepts in the pathogenesis of age-related macular degeneration. Arch. Ophthalmol. 2004, 122:598-614.
245. Zayit-Soudry S., Duncan J.L., Syed R., Menghini M., Roorda A.J. Cone structure imaged with adaptive optics scanning laser ophthalmoscopy in eyes with nonneovascular age-related macular degeneration. Investig. Ophthalmol. Vis. Sci. 2013, 54:7498-7509.
246. Zhang L., Lee K., Niemeijer M., Mullins R.F., Sonka M., Abràmoff M.D. Automated segmentation of the choroid from clinical SD-OCT. Investig. Ophthalmol. Vis. Sci. 2012, 53:7510-7519.
247. Zhang L., Sonka M., Folk J.C., Russell S.R., Abramoff M.D. Quantifying disrupted outer retinal-subretinal layer in SD-OCT images in choroidal neovascularization. Investig. Ophthalmol. Vis. Sci. 2014, 55:2329-2335.
248. Zhu D., Deng X., Xu J., Hinton D.R. What determines the switch between atrophic and neovascular forms of age related macular degeneration? - the role of BMP4 induced senescence. Aging 2009, 1:740-745.
249. Zweifel S.A., Engelbert M., Laud K., Margolis R., Spaide R.F., Freund K.B. Outer retinal tubulation: a novel optical coherence tomography finding. Arch. Ophthalmol. 2009, 127:1596-1602.